Roth Capital Maintains Buy On Sarepta Following First Patient Dosed In Study Of Eteplirsen
Roth Capital analyst Debjit Chattopadhyay maintained Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $22 price target, as the company initiated dosing in a clinical study of eteplirsen, the Company’s lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD), in patients who are non-ambulant or who have advanced DMD and don’t meet a minimum 6-minute walk test score at baseline.
Chattopadhyay noted, “Sarepta has initiated dosing of non-ambulant patients as a part of its pivotal program. While these 20 patients won’t contribute towards the primary efficacy measure, safety data along with other functional measures, will complement the NDA submission. Ambulant patient dosing is likely to begin next week. At current levels Sarepta offers a compelling risk reward profile, in our view.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of -10.2% and a 43.1% success rate. Chattopadhyay has a -26.3% average return when recommending SRPT, and is ranked #3311 out of 3369 analysts.